About MediWound
MediWound is a company based in Yavne (Israel) founded in 2001 by Lior Rosenberg.. MediWound has raised $18 million across 6 funding rounds from investors including Clal Biotechnology Industries, MTEC and Point72. The company has 111 employees as of December 31, 2024. MediWound has completed 1 acquisition, including PolyHeal. MediWound offers products and services including NexoBrid, EscharEx, and MW005. MediWound operates in a competitive market with competitors including Ilya Pharma, QBiotics, Resolution Therapeutics, SanuWave and Haemostatix, among others.
- Headquarter Yavne, Israel
- Employees 111 as on 31 Dec, 2024
- Founders Lior Rosenberg
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mediwound Ltd.
-
Annual Revenue
$20.22 M8.22as on Dec 31, 2024
-
Net Profit
$-30.22 M-350.03as on Dec 31, 2024
-
EBITDA
$-17.9 M-26.07as on Dec 31, 2024
-
Total Equity Funding
$18 M (USD)
in 6 rounds
-
Latest Funding Round
$17.71 M (USD), Grant
Jul 16, 2024
-
Investors
Clal Biotechnology Industries
& 10 more
-
Employee Count
111
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MediWound
MediWound is a publicly listed company on the NASDAQ with ticker symbol MDWD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of MediWound
MediWound offers a comprehensive portfolio of products and services, including NexoBrid, EscharEx, and MW005. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enzymatic product for removing nonviable burn tissue safely.
Therapy for debriding chronic wounds and promoting healing.
Topical biologic for treating low-risk basal cell carcinoma.
Unlock access to complete
Unlock access to complete
Funding Insights of MediWound
MediWound has successfully raised a total of $18M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $17.71 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Grant — $17.7M
-
First Round
First Round
(23 Jun 2013)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2024 | Amount | Grant - MediWound | Valuation |
investors |
|
| Dec, 2023 | Amount | Grant - MediWound | Valuation |
investors |
|
| Feb, 2023 | Amount | Post-IPO - MediWound | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in MediWound
MediWound has secured backing from 11 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Clal Biotechnology Industries, MTEC and Point72. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Venture capital investments in healthcare are focused on by aMoon.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by MediWound
MediWound has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include PolyHeal. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Microsphere-based technology is utilized for active wound healing products.
|
1996 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - MediWound
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mediwound Comparisons
Competitors of MediWound
MediWound operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ilya Pharma, QBiotics, Resolution Therapeutics, SanuWave and Haemostatix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biological drugs for skin and mucosa wound treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules from plant extracts are developed for medical applications.
|
|
| domain | founded_year | HQ Location |
Macrophage cell therapies are developed for inflammatory and liver diseases.
|
|
| domain | founded_year | HQ Location |
Noninvasive devices and biologics for wound healing are developed.
|
|
| domain | founded_year | HQ Location |
Developing new class of peptide based coagulant
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mediwound
Frequently Asked Questions about MediWound
When was MediWound founded?
MediWound was founded in 2001 and raised its 1st funding round 12 years after it was founded.
Where is MediWound located?
MediWound is headquartered in Yavne, Israel. It is registered at Yavne, Central District, Israel.
Who is the current CEO of MediWound?
Gal Cohen is the current CEO of MediWound.
Is MediWound a funded company?
MediWound is a funded company, having raised a total of $18M across 6 funding rounds to date. The company's 1st funding round was a Post-IPO of $27.5M, raised on Jun 23, 2013.
How many employees does MediWound have?
As of Dec 31, 2024, the latest employee count at MediWound is 111.
What is the annual revenue of MediWound?
Annual revenue of MediWound is $20.22M as on Dec 31, 2024.
What does MediWound do?
MediWound was founded in 2001 in Yavne, Israel, within the biotechnology sector. Enzymatic technologies are utilized to create therapies for wound care, burns, and tissue regeneration. Products such as NexoBrid for burn debridement, EscharEx for chronic wounds, and MW005 for non-melanoma skin cancers are included in the portfolio. Operations focus on biological medicinal products for dermatological applications.
Who are the top competitors of MediWound?
MediWound's top competitors include Ilya Pharma, SanuWave and QBiotics.
What products or services does MediWound offer?
MediWound offers NexoBrid, EscharEx, and MW005.
Is MediWound publicly traded?
Yes, MediWound is publicly traded on NASDAQ under the ticker symbol MDWD.
How many acquisitions has MediWound made?
MediWound has made 1 acquisition, including PolyHeal.
Who are MediWound's investors?
MediWound has 11 investors. Key investors include Clal Biotechnology Industries, MTEC, Point72, Deep Insight, and Israel Biotech Fund.
What is MediWound's ticker symbol?
The ticker symbol of MediWound is MDWD on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.